Hep C drugs approved for kidsFDA approved supplemental applications for 2 primary hepatitis C medications to be used in children for the first time.
Watch list 2016: Top therapeutic areas
Watch list 2016: Top therapeutic areasExperts say you should follow these 6 therapeutic areas.
FDA approves Harvoni for new usesFDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.
FDA approves Daklinza for hepatitis C genotype 3On July 24, FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections.
Harvoni could save US, Europe $3.2 billionThe higher cure rate of treating hepatitis C patients with a combination of ledipasvir and sofosbuvir (Harvoni) led to substantially better work productivity, according to a new study. In fact, improved work productivity and lack of absenteeism could save the United States and 5 European countries more than $3.2 billion a year.
FDA approves changes to hep C drug label to include new warningsFDA has approved changes to the hepatitis C antiviral simeprevir (Olysio, Janssen) label to include new warnings about serious symptomatic bradycardia—slowing of the heart rate—when co-administered with antiarrhythmic drug amiodarone and antiviral sofosbuvir (Solvaldi, Gilead).
New hep C drugs will strain the system: MD Anderson studyThe cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies is likely to place a tremendous economic burden on the country’s healthcare system, according to a study published in the March 17 issue of the Annals of Internal Medicine.
FDA warns about serious reactions to Harvoni, SovaldiBoth the Food and Drug Administration (FDA) and Harvoni and Sovaldi maker Gilead are warning Hepatitis C patients about serious bradycardia when the drugs are combined with certain other medications.
[BLOG] Pipeline advancement responsible for upturn in global pharma R&DThe world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year. According to our new Global Pharmaceutical Benchmark Report, Roche was the R&D spending leader, outlaying nearly $10 billion in 2013. Meanwhile, Novartis and Johnson & Johnson (J&J) increased their R&D spend the most between 2012 and 2013, with each adding around $500 million to their respective clinics. Novartis’ R&D spending grew by 5.6% to $9.8 billion, and J&J spent $8.2 billion, which was up by 6.8% from 2012.
CVS Health commits to Gilead's hepatitis C drugsClose on the heels of Express Scripts’ decision to make AbbVie’s Viekira the exclusive hepatitis C treatment in its formulary, CVS Health said it would make Gilead Sciences’ Harvoni and Sovaldi the exclusive option for patients on its commercial drug list, as well as those on Medicare Part D and Medicaid.